Non Cancer Pain Management for New Mexico Advanced Practice Nurses

27.95
Online
Mandatory
About the Course

Advanced Practice Nurses (APNs) have a responsibility to understand the appropriate use of opioid medications and the risks inherent to this category of therapeutic products. It is critical to be well-versed in the federal and state laws governing the prescribing of these products. Effective June 14, 2019, the New Mexico legislature passed requirements governing the prescribing of prescription opioid medications. This course is specifically designed to meet the continuing education requirements as described in Rule 9, Section 8 by the New Mexico Board of Nursing that requires five (5) contact hours of non-cancer pain management for license renewal. The course provides an overview of the legal requirements governing the prescribing of opioids in New Mexico and outlines the APNs responsibilities under state law. A solid understanding of non-cancer pain management, opioids, their use, misuse and potential solutions to this public health issue will greatly contribute to improved patient health and quality of life.

Learning Outcomes:
Upon completion of this course, the learner will be able to:
  • Understand the pharmacology and risk associated with opioid use.
  • Suggest one factor that may have contributed to the current increase in opioid usage.
  • Explain one regulatory objective of the Controlled Substances Act of 1970 (CSA).
  • Name one medication classified as Schedule IV by the CSA.
  • Provide a reason for why opioid analgesics may not be an ideal first line treatment option for pain.
  • Describe the potential value of toxicology screens as a part of opioid therapy.
  • State one category of medications that should be used with caution in conjunction with opioids.
  • Provide one guideline for consideration when initiating opioid therapy for pain management.
  • Name a tool with some utility for characterizing the risk of opioid addiction.
  • Explain the risks of renarcotization.

About the Author:
Bradley Gillespie, PharmD

Bradley Gillespie, PharmD, trained as a clinical pharmacist and has practiced in an industrial setting for the past 25+ years. His initial role was as a Clinical Pharmacology and Biopharmaceutics reviewer at the FDA, followed by 20 years of leading early development programs in the pharma/biotech/nutritional industries. In addition to his industrial focus, he remains a registered pharmacist, enjoys mentoring drug development scientists and health professionals, leading workshops, and developing continuing education programs for pharmacy, nursing, and other medical professionals.
Want Unlimited CE? Become a Member

Non Cancer Pain Management for New Mexico Advanced Practice Nurses

27.95
About the Course

Advanced Practice Nurses (APNs) have a responsibility to understand the appropriate use of opioid medications and the risks inherent to this category of therapeutic products. It is critical to be well-versed in the federal and state laws governing the prescribing of these products. Effective June 14, 2019, the New Mexico legislature passed requirements governing the prescribing of prescription opioid medications. This course is specifically designed to meet the continuing education requirements as described in Rule 9, Section 8 by the New Mexico Board of Nursing that requires five (5) contact hours of non-cancer pain management for license renewal. The course provides an overview of the legal requirements governing the prescribing of opioids in New Mexico and outlines the APNs responsibilities under state law. A solid understanding of non-cancer pain management, opioids, their use, misuse and potential solutions to this public health issue will greatly contribute to improved patient health and quality of life.

Learning Outcomes:
Upon completion of this course, the learner will be able to:
  • Understand the pharmacology and risk associated with opioid use.
  • Suggest one factor that may have contributed to the current increase in opioid usage.
  • Explain one regulatory objective of the Controlled Substances Act of 1970 (CSA).
  • Name one medication classified as Schedule IV by the CSA.
  • Provide a reason for why opioid analgesics may not be an ideal first line treatment option for pain.
  • Describe the potential value of toxicology screens as a part of opioid therapy.
  • State one category of medications that should be used with caution in conjunction with opioids.
  • Provide one guideline for consideration when initiating opioid therapy for pain management.
  • Name a tool with some utility for characterizing the risk of opioid addiction.
  • Explain the risks of renarcotization.

About the Author:
Bradley Gillespie, PharmD

Bradley Gillespie, PharmD, trained as a clinical pharmacist and has practiced in an industrial setting for the past 25+ years. His initial role was as a Clinical Pharmacology and Biopharmaceutics reviewer at the FDA, followed by 20 years of leading early development programs in the pharma/biotech/nutritional industries. In addition to his industrial focus, he remains a registered pharmacist, enjoys mentoring drug development scientists and health professionals, leading workshops, and developing continuing education programs for pharmacy, nursing, and other medical professionals.